Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$50 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.2
Industry P/E
--
EV/EBITDA
-1.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$0.3
EPS
$-0.3
Face value
--
Shares outstanding
159,615,766
CFO
$-228.85 Mln
EBITDA
$-279.13 Mln
Net Profit
$-360.82 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
| -20.8 | -11.0 | -20.8 | -85.3 | -22.4 | -37.2 | -- |
|
BSE Sensex*
| -14.4 | -10.9 | -15.0 | -4.7 | 7.1 | 7.7 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
| -88.1 | 51.0 | 208.0 | -53.1 | -55.3 | 9.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
|
0.3 | 50.4 | 0.5 | -41.9 | -8,100.3 | -82.2 | -- | 1.2 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 228.2 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of... osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom. Address: One Cavendish Place, London, United Kingdom, W1G 0QF Read more
Co-Founder, CEO & Executive Director
Dr. Denise Vera Scots-Knight Ph.D.
Co-Founder, CEO & Executive Director
Dr. Denise Vera Scots-Knight Ph.D.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Mereo BioPharma Group plc - ADR is $0.33 (NASDAQ) as of 01-Apr-2026 16:26 EDT. Mereo BioPharma Group plc - ADR has given a return of -22.43% in the last 3 years.
Since, TTM earnings of Mereo BioPharma Group plc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.58
|
1.62
|
|
2024
|
-11.98
|
8.50
|
|
2023
|
-10.35
|
6.03
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Mereo BioPharma Group plc - ADR are Rs 3.05 and Rs 0.20 as of 02-Apr-2026.
Mereo BioPharma Group plc - ADR has a market capitalisation of $ 50 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Mereo BioPharma Group plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.